Olumiant ® (baricitinib) tabletter

För fullständig produktresumé för Olumiant se FASS.

Denna information är endast avsedd för sjukvårdspersonal verksam i Sverige och som svar på din fråga. Informationen nedan är på engelska

Olumiant® ▼ (baricitinib): Allvarliga Hjärt- Kärlbiverkningar

I det kliniska utvecklingsprogrammet för baricitinib var behandling med BARI hos patienter med måttlig till svår aktiv RA inte förknippad med en ökad risk för allvarliga hjärt och kärlbiverkningar.

Incidence of Cardiovascular Events in Baricitinib Clinical Trials

Cardiovascular Risk in Patients With Rheumatoid Arthritis

Patients with RA have an increased CV risk due to the nature of RA itself.1 Accelerated atherosclerosis caused by inflammation is the hallmark of CV disease in RA.2

An assessment of CV events was incorporated into the BARI phase 3 clinical development program as an event of interest.

Exclusion Criteria Related to Cardiovascular Events in the Baricitinib Rheumatoid Arthritis Clinical Development Program

In the 4 phase 3 clinical trials, RA-BEGIN, RA-BEAM, RA-BUILD, and RA-BEACON, eligibility criteria relating to CV events excluded patients who

  • have screening electrocardiogram abnormalities that, in the opinion of the investigator or the sponsor, are clinically significant and indicate an unacceptable risk for the patient’s participation in the study, such as Fridericia’s corrected QT interval >500 milliseconds

  • within 12 weeks of study entry have experienced

    • MI

    • unstable ischemic heart disease

    • stroke, or

    • have New York Heart Association stage IV heart failure.3

Cardiovascular Event Adjudication Process in Rheumatoid Arthritis Clinical Trials

An independent, external CEC was established to adjudicate potential CV adverse events for the BARI phase 3 clinical studies. The CEC remained blinded to treatment assignments and assessed each potential event individually.3

Potential CV events were identified to be sent for adjudication

  • by the investigator indicating that a potential event occurred, or

  • by sponsor and independent CEC review of SAE and TEAE MedDRA preferred terms according to a prespecified list to ensure that potential CV events that qualified for adjudication were sent for review.3

Positively adjudicated CV events were categorized as either

  • MACE, which included

    • CV death

    • MI

    • stroke, or

  • other CV event, which included

    • hospitalization for unstable angina

    • hospitalization for heart failure

    • serious arrhythmia

    • resuscitated sudden death

    • cardiogenic shock, or

    • coronary revascularizations.3,4

All cases of death, regardless of the investigator’s assessment as to the cause of death, were also sent for adjudication.3

Integrated Datasets Used to Evaluate Major Adverse Cardiovascular Events in Rheumatoid Arthritis Clinical Trials

The integrated datasets used to evaluate cases of MACE are described in more detail in Table 1. The exposure information, including median, maximum and total PYE, and cut-off date described in the table is applicable to the data presented below unless otherwise specified.

Table 1. Integrated Analysis Datasets Used to Evaluate Safety in Rheumatoid Arthritis Clinical Trials3,5,6

Analysis Set


7-Study Placebo-Controlled Dataset


Compares BARI 4 mg vs placebo

Includes patients with RA from 3 phase 2 and 4 phase 3 studies who were randomized to

  • BARI 4 mg (N=1142, [exposure through 24 weeks: PYE=471.8, median exposure=169 days, maximum exposure=211 days]), or

  • placebo (N=1215, [exposure through 24 weeks: PYE=450.8, median exposure=166 days, maximum exposure=235 days]).

Patients in the placebo group could have been taking

  • background MTX, or

  • in some studies, other conventional DMARD therapy.

Evaluation time periods included

  • through the 12-week placebo-controlled period in phase 2 studies

  • through 16 weeks of assigned treatment before any opportunity for rescue therapy in phase 3 studies, and

  • through 24 weeks of assigned treatment or until rescue in phase 3 studies.

BARI 2 mg Analysis Set

BARI 2 mg data is derived from 4 studies in which both BARI 2 mg (N=479, [exposure through 24 weeks: PYE=185.8, median exposure=168 days, maximum exposure=197 days]) and BARI 4 mg were options during randomization (JADA, JADN, RA-BUILD, RA-BEACON).

4-Study Extended Dataset


Compares BARI 4 mg vs BARI 2 mg including extended evaluations

Includes patients with RA from 2 phase 2 and 2 phase 3 studies and any further exposure for those patients in the phase 3 extension study, RA-BEYOND, who were randomized to

  • BARI 4 mg (N=479, PYE=781.1, median exposure=342 days, maximum exposure=3085 days), or

  • BARI 2 mg (N=479, PYE=774.9, median exposure=257 days, maximum exposure=2370 days).

Evaluation time period included randomization through last available observation incorporating extension data through 01 September 2019 unless otherwise specified.

All BARI RA Dataset


No between-group comparisons

Includes patients with RA (N=3770, PYE=13,148, median exposure=4.2 yrs, maximum exposure=8.4 yrs) from 1 phase 1, 3 phase 2, 5 phase 3 studies, and 1 phase 3 extension study who received BARI at a variety of doses, including

  • BARI 4 mg (n=3400)

  • BARI 2 mg (n=1077), and

  • BARI 1 mg, 7 mg, 8 mg, and 10 mg QD doses not evaluated in confirmatory studies.

Patients had to have received at least 1 dose of BARI and could have received different doses throughout the trials.

Evaluation time period is all exposure time points including after rescue or changes in study drug through 01 September 2019 unless otherwise specified.

Abbreviations: BARI = baricitinib; DMARD = disease-modifying antirheumatic drug; MTX = methotrexate; PYE = patient-years of exposure; QD = once daily; RA = rheumatoid arthritis.

a Patients with renal function impairment who were randomized to BARI 4 mg, but treated with the 2-mg dose were analyzed in the BARI 4-mg group.

Incidence of Major Adverse Cardiovascular Events in the Baricitinib Rheumatoid Arthritis Clinical Development Program

Incidence rates were calculated as the number of patients with an event per 100 patient-years of exposure time, with exposure censored at time of event.6

7-Study Placebo-Controlled Dataset

In the combined 7-study dataset up to week 24, the number of patients with at least 1 positively adjudicated MACE was

  • 3 (IR=0.7) in the BARI 4-mg group

  • 0 in the BARI 2-mg group, and

  • 2 (IR=0.5) in the placebo group.6

4-Study Extended Dataset

In the combined 4-study extended dataset, the number of patients with at least 1 positively adjudicated MACE was

  • 3 (0.7%; EAIR=0.40) in the BARI 2-mg group, and

  • 2 (0.5%; EAIR=0.29) in the BARI 4-mg group.3

All BARI RA Dataset

In the All BARI RA dataset, there were 63 MACE across all BARI doses and exposure durations. The incidence rate was 0.5 events per 100 PYE.5

Figure 1 displays the incidence rate for patients in the All BARI RA dataset with positively adjudicated MACE overall and by 12-month intervals. The rate of MACE does not appear to increase with duration of BARI exposure.7

Figure 1. Incidence Rate of Positively Adjudicated MACE by Time Periods in RA Clinical Studies7

Abbreviations: BARI = baricitinib; IR = incidence rate; MACE = major adverse cardiovascular events; PYE = patient-years of exposure; RA = rheumatoid arthritis.


1. Kume K, Amano K, Yamada S. AB0463 Tofacitinib improves arterial stiffness with methotrexate-resistant active rheumatoid arthritis: a cohort study [abstract]. Ann Rheum Dis. 2014;73(suppl 2):961. http://dx.doi.org/10.1136/annrheumdis-2014-eular.1019

2. Sen D, Gonzalez-Mayda M, Brasington RD, Jr. Cardiovascular disease in rheumatoid arthritis. Rheum Dis Clin North Am. 2014;40(1):27-49. http://dx.doi.org/10.1016/j.rdc.2013.10.005

3. Data on file, Eli Lilly and Company and/or one of its subsidiaries.

4. Weinblatt M, Taylor PC, Burmester GR, et al. Cardiovascular safety – update from up to 6 years of treatment with baricitinib in rheumatoid arthritis clinical trials [abstract]. Arthritis Rheumatol. 2018;70(suppl 10):2815. https://acrabstracts.org/abstract/cardiovascular-safety-update-from-up-to-6-years-of-treatment-with-baricitinib-in-rheumatoid-arthritis-clinical-trials/

5. Genovese MC, Smolen JS, Takeuchi T, et al. Safety profile of baricitinib for the treatment of rheumatoid arthritis up to 8.4 years: an updated integrated safety analysis [abstract]. Ann Rheum Dis. 2020;79(suppl 1):638. http://scientific.sparx-ip.net/archiveeular/?c=a&view=4&item=2020FRI0123

6. Genovese MC, Smolen JS, Tsutomu T et al. Safety profile of baricitinib for the treatment of rheumatoid arthritis over a median of 3 years of treatment: an updated integrated safety analysis. Lancet Rheumatol. 2020;2(6):E347-E357. https://doi.org/10.1016/S2665-9913(20)30032-1

7. Genovese MC, Smolen JS, Takeuchi T, et al. Safety profile of baricitinib for the treatment of rheumatoid arthritis up to 8.4 years: an updated integrated safety analysis. Poster presented at: European League Against Rheumatism Virtual Congress; June 3-6, 2020.


BARI = baricitinib

CEC = Clinical Endpoint Committee

CV = cardiovascular

EAIR = exposure-adjusted incidence rate

IR = incidence rate

IV = intravenous

MACE = major adverse cardiovascular event

MedDRA = Medical Dictionary for Regulatory Activities

MI = myocardial infarction

PYE = patient-years of exposure

RA = rheumatoid arthritis

SAE = serious adverse event

TEAE = treatment-emergent adverse event

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Datum fӧr senaste ӧversyn 2019 M05 31

Kontakta Medicinsk Information på Lilly

Kontakta oss på telefon

Kontorstid vardagar 9.00-17.00

Eller så kan du

Klicka för att chatta är tillgänglig

Klicka för att chatta är offline

Skriv din fråga till oss